ABCL Abcellera Biologics Inc

P/E --
Forward P/E 27.55
Price/Sales 62.1
Beta 1.41
Div Yield --
Market Cap --

Company Analysis

Latest News

🔴 Abcellera Biologics falls 4.1% — Biotech Sector Declines Amid Broad Market Rotation

With Biotech (XBI) down 2.1%, this looks like a sector-led move rather than a company-specific surprise. The biotechnology sector, as represented by the XBI...

🔴 Abcellera Biologics is trading 4.56% down in pre-market as hotter-than-expected U.S. inflation raises rate-hike concerns

Abcellera Biologics is trading at $11.81, down 4.56% in pre-market on October 15 amid broader risk-off sentiment after hotter-than-expected U.S. inflation...

🟢 Abcellera Biologics is trading 4.3% up in pre-market

Abcellera Biologics is trading 4.3% up at $13.08 in pre-market on October 12; the cause remains unclear. - No fresh company announcement or reliable report...

🟢 Abcellera Biologics rises 5.0% — Biotech Sector Rallies on Strong IPO Debuts and M&A Activity

With Biotech (XBI) up 2.5%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector is experiencing a significant rally,...

🔴 Abcellera Biologics is trading 4.1% down today with no clear company-specific explanation

Abcellera Biologics is trading 4.1% down now at $12.31, with no clear company-specific announcement explaining the October 8 decline surfaced in available...

🔴 Abcellera Biologics is trading 4.1% down today amid biotech-sector weakness

Abcellera Biologics is trading at $13.21, down 4.14%, with biotech-sector weakness providing context, but no clear company-specific explanation was...

🟢 Abcellera Biologics is trading 4.43% up with no company-specific catalyst identified

Abcellera Biologics is trading 4.43% up at $14.39 as of 9:43 a.m. EST on October 6, 2026; no new company-specific announcement explaining the move was found. -...

🔴 Abcellera Biologics is trading 4.22% down — no clear catalyst identified

Abcellera Biologics is trading 4.22% down at $13.97, with no clear catalyst identified for the October 1 decline. - The scheduled ABCL635 Phase 2 data...

🟢 Abcellera Biologics is trading 4.3% up today after JPMorgan's Overweight initiation and $17 target

Abcellera Biologics is trading 4.34% up at $14.52 after JPMorgan initiated coverage with an Overweight rating and a $17 target, cited as the immediate...

🟢 Abcellera Biologics is trading 10.7% up with no clear company-specific catalyst

Abcellera Biologics is trading 10.7% up at $14.05, though the cause of the intraday rise remains unclear. - No clear new company-specific announcement on...

🟢 Abcellera Biologics is trading 4.17% up; catalyst remains unclear

Abcellera Biologics is trading at $13.23, up 4.17%, with the specific reason for its September 28 intraday rise still unclear. - No clear company-specific...

🔴 Abcellera Biologics is trading 4.06% down today as 10-year Treasury yield hits a 19-year high

Abcellera Biologics is trading 4.06% down at $11.81, with macro-driven inflation and higher-for-longer rate concerns pressuring biotech valuations. - The...

🔴 Abcellera Biologics is trading 4.1% down today as rising oil and Treasury yields pressure valuations

Abcellera Biologics is trading 4.1% lower at $12.13 as rising crude oil prices and a 4.99% 10-year Treasury yield pressure equity valuations. - No fresh...

🟢 Abcellera Biologics is trading 11.47% up today after announcing an ABCL635 Phase 2 data presentation

Abcellera Biologics is trading at $13.01, up +11.47%, after announcing on September 16, 2026, that it will present Phase 2 data for ABCL635 at the...

Abcellera's Hot-Flash Drug Sends Shares Soaring — But Can a Single Shot Justify a $3.8 Billion Bet?

Abcellera's Hot-Flash Drug Sends Shares Soaring — But Can a Single Shot Justify a $3.8 Billion Bet?

Shares of AbCellera Biologics surged +7.5% to $12.55 on September 17 after the company announced it will present Phase 2 clinical data for its lead menopause...

🟢 Abcellera Biologics is trading 7.5% up today after announcing Phase 2 ABCL635 data presentation

Abcellera Biologics is trading at $12.55 (+7.54%) after announcing it will present Phase 2 ABCL635 data at the IMS World Congress on Menopause. - The...

🟢 Abcellera Biologics is trading 6% up today amid biotech-sector rally after Fed decision

Abcellera Biologics is trading 6% up at $12.37, primarily supported by a 2.55% biotech-sector rally and stronger market sentiment following the Federal Reserve...

🟢 Abcellera Biologics Inc is trading 4.48% up

ABCL is trading at $11.67, up 4.48%.

🟢 Abcellera Biologics is trading 4.16% up today as broader markets rally after inflation data

Abcellera Biologics is trading 4.16% up at $10.89 as broader markets rally after inflation data. - The S&P 500, Nasdaq Composite, and Dow Jones are each up...

🔴 Abcellera Biologics is trading 4% down today as risk-off selling pressures growth stocks

Abcellera Biologics is trading at $10.60, down 4.07%, as broader risk-off selling pressured growth stocks on September 10, 2026. - The S&P 500, Nasdaq...